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Background: Zoledronic acid is a potent inhibitor of osteoclast-mediated bone resorption and has been widely
used in bone metastasis malignancies and postmenopausal osteoporosis as a preventive therapy against skeletal-
related events. The purpose of this study was to evaluate the clinical outcome of zoledronic acid as an adjuvant
therapy for patients with early stage breast cancer.
Patients and methods: Entries in the PubMed and EMBASE databases up to 12 July 2013 were systematically
reviewed. Online abstracts from the proceedings of the Annual Meetings of the American Society of Clinical
Oncology (ASCO) (1992–2013) and the San Antonio Breast Cancer Symposium (SABCS) (2004–2013) were also
reviewed. Primary endpoints included overall survival (OS) and disease-free survival (DFS), while secondary
endpoints included bone metastasis-free survival (BMFS), distant metastasis-free survival (DMFS), and fracture-free
rate (FFR).
Results: A total of eight studies including 3,866 subjects and 3,864 controls met our search criteria and were
evaluated. The use of zoledronic acid was found to improve OS (relative risk (RR), 0.88; 95% confidence interval (CI),
0.77–1.01; p-value = 0.06) and DMFS (RR, 0.77; 95% CI, 0.60–1.00; p-value = 0.05). Furthermore, statistically significant
benefits were associated with BMFS (RR, 0.81; 95% CI, 0.66–0.99; p-value = 0.04) and FFRs (RR, 0.75; 95% CI, 0.61–0.92;
p-value = 0.007). In contrast, there was no significant difference in DFS with the application of zoledronic acid (RR, 0.88;
95% CI, 0.72–1.09; p-value = 0.24). Sensitivity analysis further identified the improvement of 5-year OS for the adjuvant
zoledronic acid therapy in early stage breast cancer patients (RR, 0.86; 95% CI, 0.75–0.99; p-value = 0.03), while a
borderline statistically significant benefit was observed for 5-year DFS (RR, 0.90; 95% CI, 0.81–1.00; p-value = 0.06).
Conclusion: Zoledronic acid as an adjuvant therapy appears to improve the 5-year OS rate for early stage breast
cancer patients, and was associated with a protective effect for the bone metastases and fractures evaluated in more
than 7,000 patients. However, further research is needed to confirm our findings, and sub-group analyses according to
menopause status or hormone status may provide further insight.
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Breast cancer is the most commonly diagnosed malig-
nancy and the third leading cause of cancer death among
women worldwide [1]. Moreover, despite the application
of neoadjuvant and adjuvant therapies to patients in the
early stages of breast cancer, this disease remains a major
public health challenge. In addition, since bone is the most
common site for breast cancer metastasis events [2],
skeletal-related events (SREs) can also develop, and these
include hypercalcaemia, bone pain, pathological fractures,
and spinal cord compression [3].
Bisphosphonates (BPs) are potent inhibitors of osteoclast-
mediated bone resorption. Consequently, BPs have been
used to treat bone metastasis malignancies [4,5] and post-
menopause osteoporosis as a preventive therapy against
SREs [6]. Furthermore, BPs are increasingly being used for
the treatment of early stage breast cancer patients, based
on level-one evidence that BPs, particularly zoledronic acid,
effectively prevent cancer treatment-induced bone loss
(CTIBL) in breast cancer patients receiving chemotherapy
and/or estradiol-lowering endocrine therapies [7-10]. Emer-
ging data from preclinical studies have also shown a direct
anti-tumour role for zoledronic acid in the inhibition of
tumour cell adhesion, invasion, and proliferation, as
well as in the induction of apoptosis as demonstrated
in multiple human tumour cell lines [11]. An indirect
anti-tumour role for zoledronic acid also includes the
inhibition of angiogenesis [12]. Considerable evidence
further suggests that nitrogen-containing BPs exhibit
a higher potency by exerting additive or synergistic
interactions with standard cytotoxic agents [13].
Several large-scale randomized controlled trials of adju-
vant zoledronic acid therapy for patients with breast can-
cer have recently been completed, and the results are
somewhat controversial [14-17]. Therefore, a comprehen-
sive, systematic review and meta-analysis was performed
to evaluate the clinical outcome associated with the use of
zoledronic acid as an adjuvant therapy for the treatment
of patients with early stage breast cancer.
Results
Selection of studies
A total of 419 citations were obtained from electronic
searches of the Pubmed and EMBASE databases. Upon
review of these abstracts, 402 articles were excluded.
Based on the inclusion criteria established for the
present study, an additional nine articles were excluded.
Thus, eight randomized controlled trials were examined
[14-21], which included 7,730 patients with early stage
breast cancer.
Study characteristics
All eight studies were multicentre prospective clinical
trials. The level of evidence provided by each article wasgraded with a Jadad quality score, and these values ranged
from 2 to 5 (Table 1). Assessment of risk of bias also iden-
tified an unclear or high risk for these studies.
Of the eight studies, the Z-FAST, ZO-FAST, and E-ZO-
FAST studies [16,17,22], as well the study by Takahashi
et al. [23], included hormone responsive postmenopausal
women. However, while the Takahashi trial enrolled
Japanese women, the other three studies primarily in-
cluded Caucasian women. The ABCSG-12 trial [15]
included premenopausal women with endocrine re-
sponsive breast cancers in their early stages. However,
these patients were treated with goserelin for ovarian sup-
pression, and as a result, these patients were considered
postmenopausal. In the trial conducted by Leal et al. [19],
postmenopausal women regardless of their hormone
status were included. In the AZURE [14] and Aft et al.
[18] trials, both postmenopausal and pre/perimenopausal
breast cancer patients were enrolled. Furthermore, while
Aft et al. represents a phase II clinical trial, the Z-FAST,
ZO-FAST, E-ZO-FAST, ABCSG-12, AZURE, Takahashi
et al., and Leal et al. trials were phase III clinical trials.
For two of the studies examined [20,21], data were
obtained from updated study reports that were presented
at the American Society of Clinical Oncology (ASCO)
meetings and included a longer follow-up period (36
months). In contrast, the follow-up period of each of
the other studies was approximately 5 years [14-19].
A summary of the studies included in this meta-
analysis is provided in Table 2.
Primary endpoints: overall survival (OS) and disease-free
survival (DFS)
OS was assessed in seven studies (including 7,541 pa-
tients). Zoledronic acid was associated with a borderline
statistically significant improvement in OS (relative risk
(RR), 0.88; 95% confidence interval (CI), 0.77–1.01; p-
Table 2 Summary of the trials examined T
Study year Intervention Bisphosphonate acid
administration




ABCSG-12 (2011) [15] Zoledronic acid
Observation




AZURE (2011) [14] Zoledronic acid
Observation
4 mg IV every 4 wks × 6, then
3 mos × 8 and 6 mos × 5
Standard treatment 5 1681 59
1678
E-ZO-FAST (2009) [20] Upfront zol 4 mg IV every 6 mos Letrozol 5 263 36
Delayed zol 264
Z-FAST (2012) [17] Upfront zol 4 mg IV every 6 mos Letrozol 5 300 61
Delayed zol 300
ZO-FAST (2013) [16] Upfront zol 4 mg IV every 6 mos Letrozol 5 532 60
Delayed zol 533
Talahashi et al., (2013) [21] Upfront zol 4 mg IV every 6 mos Letrozol 1 94 36
Delayed zol 95
Leal et al., (2010) [19] Zoledronic acid
Observation
4 mg IV every 3 mos Standard treatment 1 36 96
32
Aft et al., (2012) [18] Zoledronic acid
Observation
4 mg IV every 3 wks Neoadjuvant chemotherapy 60 61.9
59
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eity, I2 = 20%, p-value = 0.27) (Figure 1A). In contrast,
DFS was assessed in eight studies (including 7,730 pa-
tients), and no difference in the use or absence of
zoledronic acid as an adjuvant was observed (RR, 0.88;
95% CI, 0.72–1.09; p-value = 0.24; random-effect, signifi-
cant studies heterogeneity, I2 = 44%, p-value = 0.09)
(Figure 1B).
Secondary endpoints: bone metastasis-free survival
(BMFS), distant metastasis-free survival (DMFS), and
fracture-free rate (FFR)
BMFS was reported in five studies (including 7,354 pa-
tients), and a statistically significant benefit for BMFS was
identified with adjuvant zoledronic acid use (RR, 0.81; 95%
CI, 0.66–0.99; p-value = 0.04; fixed-effect, no significant
studies heterogeneity, I2 = 0%, p-value = 0.44) (Figure 1C).
DMFS was reported in four studies (including 3,995 pa-
tients), and showed a borderline statistically significant
benefit with adjuvant zoledronic acid use (RR, 0.77; 95% CI,
0.60–1.00; p-value = 0.05; fixed-effect, no significant studies
heterogeneity, I2 = 33%, p-value = 0.22) (Figure 1D). Lastly,
FFR was reported in six studies (including 7,543 patients),
and showed a statistically significant decrease in fracture
rates with zoledronic acid as an adjuvant (RR, 0.75; 95% CI,
0.61–0.92; p-value = 0.007; fixed-effect, no significant stud-
ies heterogeneity, I2 = 0%, p-value = 0.49) (Figure 1E).
Sensitivity analysis
Sensitivity analysis was conducted according to the follow-
up period. For two trials with a 36 month follow-up periodand fewer progressive events [20,21], these were omitted
for this analysis. For the six other studies, the 5-year OS
rate for more than 7,000 patients in the early stages of
breast cancer was found to significantly improve with
zoledronic acid as an adjuvant (RR, 0.86; 95% CI, 0.75–
0.99; p-value = 0.03; fixed-effect, no significant studies het-
erogeneity, I2 = 0%, p-value = 0.70) (Figure 2A). Moreover,
an improvement trend was observed for the 5-year DFS
rate for these same studies (RR, 0.90; 95% CI, 0.81–1.00; p-
value = 0.06; fixed-effect, no significant studies heterogen-
eity, I2 = 44%, p-value = 0.11) (Figure 2B).
Publication bias
In all of the meta-analyses performed, the funnel plots
were symmetrical. These results indicate that it is unlikely
that publication bias had a major influence on the analyses
performed (plots not shown).
Discussion
The meta-analysis performed included more than 7,000
patients and provides evidence that the use of zoledronic
acid in an adjuvant breast cancer setting improves 5-
year OS rates by 14%, reduces the risk of metastasis
events by 19%, and lowers the risk of fractures by 25%.
In contrast, the use of zoledronic acid did not improve
DFS or DMFS, although the 5-year DFS and DMFS rates
showed a borderline statistically significant benefit (the
P-values were 0.06 and 0.05, respectively).
In a meta-analysis conducted by Zhu et al., oral clodronate
was found to increase 5-year OS rates and BMFS rates
[24], and our results are consistent with these outcomes.
Figure 1 Forest plots from a meta-analysis of overall survival (A), disease-free survival (B), bone metastasis-free survival (C), distant
metastasis-free survival (D), and fracture-free rate (E) for the adjuvant use of zoledronic acid compared to the control arm.
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Figure 2 Forest plots from a sensitivity analysis of overall survival (A) and disease-free survival (B) for the adjuvant use of zoledronic
acid compared to the control arm, with a median follow-up period of 5 years.
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the direct and indirect anti-tumour activities of these
compounds, which include the prevention of tumour cell
adhesion to bone, the induction of tumour cell apoptosis,
and an inhibition of angiogenesis [11,12]. In addition,
some clinical trials have shown that zoledronic acid is able
to eliminate disseminated tumour cells (DTCs) from bone
marrow [25,26], thereby reducing the tumour burden in
bone and preventing the development and progression of
bone metastases. Zoledronic acid, as a third-generation
BP, is characterized by an imidazole ring containing two
nitrogen atoms, and appears to mediate stronger anti-
tumour effects compared with non-nitrogen-containing
BPs. For example, the presence of nitrogen has been asso-
ciated with synergistic interactions with standard cytotoxic
agents [13] and the regulation of T-cell-mediated host
immunosurveillance of tumour cells [27]. There is also
evidence that zoledronic acid may inhibit visceral metasta-
ses [28]. The Southwest Oncology Group (SWOG)-S0307
trial [29] is ongoing to compare clodronate, zoledronic
acid, and ibandronate therapies in 4,500 patients with
stage I–IIIa breast cancer. The goal is to establish the
best choice of BPs in an adjuvant setting. In addition,
the SUCCESS study [30] involving 3,700 patients in
the early stages of breast cancer has been designed to
compare DFS for patients undergoing chemotherapy
and receiving zoledronate (4 mg) for 2 years versus 5
years. The optimal treatment time and the largest cost-benefit ratio for this cohort are also being examined.
Another type of antiresorptive agent that is being
evaluated is denosumab, a fully humanised monoclonal
antibody that has been associated with a metastasis-
prevention role and is currently being investigated in adju-
vant phase III trials, including ABSCG-18 (ClinicalTrials.
gov Identifier, NCT00556374) and D-CARE (ClinicalTrials.
gov Identifier, NCT01077154).
In the current meta-analysis, zoledronic acid use was
not found to benefit DFS and DMFS. However, the lar-
gest studies performed to date [14-16,31] have shown
statistically significant benefits for the DFS and OS of
postmenopausal women. Similarly, the AZURE trial [14]
included a prespecified subgroup analysis based on age
and menopausal status. For patients who had undergone
menopause for more than 5 years before their breast
cancer diagnosis, a significant improvement in DFS and
OS was observed when zoledronic acid was received. In
contrast, no benefit was observed for premenopausal
and perimenopausal patients, or patients with unknown
menopausal status, who also received zoledronic acid. In
the ABCSG-12 trial [15], significant survival benefits
were observed for patients > 40-years-old with low estro-
gen levels resulting from gonadotropin-releasing hor-
mone use. In the final 60-month follow-up of the
ZO-FAST trial [16], a statistically significant benefit
for DFS (hazard ratio (HR) = 0.63; p-value = 0.0516)
and OS (HR = 0.50; p-value = 0.0224) was associated
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pausal for more than five years or who were > 60 years
of age when starting the study. Furthermore, based on
an analysis of stratification subgroups by the National
Surgical Adjuvant Breast and Bowel Project protocol
(B-34) [31], OS, BMFS, and non-BMFS were found to
be significantly improved with clodronate treatment in
women aged 50 years and older. In comparison, there was
little difference observed between the clodronate group
and placebo group, each containing patients younger than
50 years. In a meta-analysis conducted by Yan and Yin
[32], a better DFS outcome (RR = 0.763; p-value < 0.001)
was observed, yet a reduced risk of distant (RR = 0.744; p-
value = 0.003) and locoregional recurrence (RR = 0.508; p-
value = 0.001) was found for the postmenopause subgroup
with zoledronic acid adjuvant use. These findings suggest
that the anticancer benefits of BPs, especially zoledronic
acid, have the greatest potential in a low-estrogen environ-
ment. While the underlying mechanism for this observa-
tion remains unclear, it has been hypothesized that
estrogen’s effects on the bone microenvironment play a
key role in determining who benefits from adjuvant BP
therapy.
The results of the present study are consistent with
those of the meta-analysis conducted by Valachis et al.
[33]. However, there are additional considerations re-
garding this comparison. First, the ZO-FAST study in-
cluded in the current meta-analysis included data from a
60-month follow-up period, while the Valachis study an-
alyzed data from a 54-month follow-up period. Secondly,
the ABCSG-12 trial included 62- and 84-month follow-up
data, while 62-month follow-up data were used in the
present study. As a result, a more reliable evaluation of 5-
year OS outcome was achieved. Third, while Valachis
et al. analysed the OS for only five studies, and these did
not include the Z-FAST and E-ZO-FAST trials which had
negative results, the present meta-analysis did include all
of these studies. Correspondingly, the present study in-
cluded a robust sensitivity analysis. However, our review
had several limitations to consider as well. First, our ana-
lysis was based on published or presented data, and did
not include individual patient data. Therefore, certain de-
tails and prespecified subgroup data could not be ac-
quired. For example, the AZURE trial [14] did not provide
distant metastases data, thereby resulting in an incomplete
analysis of DMFS (p-value = 0.05) for 3,995 patients.
Secondly, subgroup analysis was not performed according
to menopausal status since the definition of postmeno-
pausal status was found to vary in the articles exam-
ined. Furthermore, the majority of the subgroup analyses
performed were unplanned, making comparisons unreli-
able. Thirdly, some of the trials considered [16,17,22,23]
included a control group that received a delayed adminis-
tration of zoledronic acid. Moreover, if this treatment wasadministered in the lumbar spine (LS) or total hip (TH),
the associated T score fell below −2.0, or a non-traumatic
fracture occurred. Therefore, a number of patients in the
control group received zoledronic acid during follow-up,
and it cannot be excluded that the effect of zoledronic acid
on patient outcome was underestimated. In addition,
these trials were designed to assess changes in bone min-
eral density (BMD) as a primary endpoint, and not DFS or
OS. Fourthly, the clinical trials included in this meta-
analysis utilized different methodologies, did not conduct
double-blinded studies, and the schedule and duration of
zoledronic acid use differed. Finally, sensitivity analysis
was performed by omitting two trials having 36-month
follow-up periods [22,23], and this omission affected the
results obtained. It is hypothesized that the reduced num-
ber of event outcomes associated with this shorter follow-
up period lacked statistical efficiency. Furthermore, the
studies in the meta-analysis were found to have an unclear
risk of bias or a high risk of bias, and the latter may have
inflated the results obtained.
Conclusion
In the meta-analysis performed, the use of intravenous
zoledronic acid as an adjuvant therapy for patients with
early stage breast cancer was found to improve 5-year
OS rates and to provide a protective effect for bone me-
tastases and fractures in more than 7,000 patients. These
clinical benefits, combined with acceptable drug-specific
toxicity, provide a positive risk-benefit profile for zoledronic
acid as an option for adjuvant breast cancer therapy. How-
ever, as additional data becomes available, an updated
meta-analysis should be performed. Furthermore, an ana-
lysis according to menopause status or hormone status
should also be conducted, and this may identify an even
greater benefit for zoledronic acid as an anti-tumour agent
in an adjuvant setting.
Materials and methods
Data sources
A systematic search of the PubMed and EMBASE data-
bases was performed of entries made through 12 July
2013. Online abstracts from the proceedings of the Annual
Meetings of the American Society of Clinical Oncology
(ASCO) (1992–2013) and the San Antonio Breast Cancer
Symposium (SABCS) (2004–2013) were also reviewed.
The terms, ‘bisphosphonates’, ‘zoledronic acid’, ‘adjuvant’,
and ‘breast cancer’ were used as key words.
Study selection
A study was considered acceptable according to the fol-
lowing inclusion criteria: (a) it represented a prospective
randomized trial, (b) the patients examined were in the
early stages of breast cancer (e.g., stage I-III), (c) zoledronic
acid was used in an adjuvant setting, (d) sufficient data
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for DFS and OS, and (e) English was the language of the
publication. When multiple articles regarding the same
trial were retrieved, the most recent or most complete
publications were selected. Reports involving advanced
breast cancer (e.g., recurrent breast cancer or metastatic
breast cancer) were excluded. Non-randomized studies
were also excluded, as well as letters to the editor, reviews,
abstracts containing insufficient detail to meet the inclu-
sion criteria, articles published in a book, and papers pub-
lished in a language other than English.
Clinical endpoints
Overall, eight studies including 3866 subjects and 3864
controls met our search criteria and were evaluated. For
each of these studies, the first authors’ name, year of
publication, number of patients randomly assigned, pa-
tient menopausal status, mean patient age, medication
strategies for treatment and control arms, and possible
outcomes at final follow-up were recorded. Primary
endpoints for these studies included OS and DFS,
while secondary endpoints included BMFS, DMFS, and
FFR. Furthermore, the outcome measures were based
on an intention-to-treat analysis. The methodological
qualities of each study were evaluated using modified
Jadad scoring (ranging from 0 to 7), with 0–3 indicating
low quality and 4–7 indicating high quality. Cochrane
Collaboration’s tool for assessing risk of bias was also
employed, which includes low, unclear, and high cat-
egories of risk of bias. Any differences in assessments
made by M.F.H and W.D.F were resolved through
discussion.
Statistical analysis
The Mantel-Haenszel method was used to calculate RRs
and their 95% CIs using either fixed- or random-effects
models, depending on the amount of heterogeneity ob-
served. The effect of heterogeneity was quantified using
I2 = 100% × (Q–df) / Q, where Q is Cochran’s χ2 hetero-
geneity statistic, df is the degrees of freedom, and I2
ranges between 0% and 100%. Moreover, I2 values of
25%, 50%, and 75% are classified as low, moderate, and
high estimates, respectively [34]. Statistically significant
heterogeneity was defined according to chi2, with a P
value < 0.1 or an I2 value > 50%. A random-effects model
meta-analysis for heterogeneous outcomes and a fixed-
effect model meta-analysis for homogeneous outcomes
were also performed [35]. For the sensitivity analysis
performed, two studies were excluded that had follow-up
periods less than five years.
Funnel plots were generated to investigate potential
publication bias. All p-values were two-sided and a
RR < 1 favored the use of zoledronic acid. All analyses
were performed using Review Manager (Version 5.2.Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2012).
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